Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update.

CONCLUSION: Topical corticosteroids with long-term emollient-based therapies remain the cornerstone of AD treatment. Systemic treatments are indicated when topical therapies and phototherapy fail to control the disease. The recent approval of dupilumab and emerging targeted therapies are expected to bring significant clinical benefit for patients whose disease is inadequately managed by existing options.
PMID: 32564976 [PubMed - as supplied by publisher]

Source: J Formos Med Assoc - June 17, 2020 Category: General Medicine Authors: Chan TC, Wu NL, Wong LS, Cho YT, Yang CY, Yu Y, Lai PJ, Chang YT, Shih IH, Lee CH, Chu CY Tags: J Formos Med Assoc Source Type: research